Abstract
摘要
相似文献
1
Autonomous units. A toolkit for autonomy.
Health Serv J. 2009 Oct 29;Suppl:3-5.
2
Cost and price in the NHS: the importance of monetary value in the decision-making framework--the case of purchasing renal replacement therapy.
Health Serv Manage Res. 1999 Feb;12(1):1-14. doi: 10.1177/095148489901200101.
3
Renal replacement therapy: how can we contain the costs?肾脏替代治疗：我们如何控制成本？
Lancet. 2014 May 24;383(9931):1783-5. doi: 10.1016/S0140-6736(14)60721-2.
4
Decrease the increase.
Tex Med. 2006 Jun;102(6):31-4.
5
Medicare HMOs reveal unique contracting strategies for new ESRD risk demonstration.医疗保险健康维护组织揭示了针对新的终末期肾病风险示范的独特签约策略。
Public Sect Contract Rep. 1997 May;3(5):74-6.
6
Costs and benefits of improving renal failure treatment--where do we go?改善肾衰竭治疗的成本与效益——我们何去何从？
Nephrol Dial Transplant. 2006 Aug;21(8):2049-52. doi: 10.1093/ndt/gfl168. Epub 2006 Apr 20.
7
8
An analysis of socialized renal medicine.社会化肾脏医学分析
Nephrol News Issues. 2005 Oct;19(11):56-7.
9
From fee-for-service to capitation: factors driving ESRD reimbursement system change.从按服务收费到按人头付费：推动终末期肾病报销系统变革的因素。
Nephrol News Issues. 1997 Apr;11(4):22-3, 31.
10
Access to Renal Replacement Therapy in South Africa-A Cry for Action.南非的肾脏替代治疗可及性——行动的呼声
Transplantation. 2020 Jun;104(6):1109-1111. doi: 10.1097/TP.0000000000003143.
Zotero 插件